| Similar Articles |
|---|
 |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.   |
Pharmaceutical Executive
September 1, 2008
Walter Armstrong |
The M&A Numbers Young & Partners crunches pharma's filings for the first half of '08. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
Bio-IT World
February 2006
G. Steven Burrill |
Outlook for '06, Look Back at '05 Overall, 2005 turned out to be an exceptional year for the biotech industry, but it wasn't all good news: Look Back at 2005... Predictions for 2006... |
BusinessWeek
June 13, 2005 |
Biotech's "Fantastic Future Ahead" Some bold predictions on what's coming for the biotech industry from Ernst & Young's Scott Morrison. |
Chemistry World
February 2008
Nuala Moran |
The Chemistry of Private Equity Private equity has transformed the chemicals industry, but can it play the same role in high-risk R&D driven companies? |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
Managed Care
May 2004 |
Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs. |
Chemistry World
February 2012 |
Navigating the stormy seas of pharma In the pharmaceutical and biotech sector, quality navigation is becoming an essential process for identifying the best route to take in order to guide business effectively in a dramatically changing environment. |
Pharmaceutical Executive
December 1, 2008
Walter Armstrong |
The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future. |
BusinessWeek
November 10, 2003
Arlene Weintraub |
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
Bio-IT World
May 2006
G. Steven Burrill |
Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies. |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
Pharmaceutical Executive
June 1, 2011 |
2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead. |
The Motley Fool
September 3, 2004
Charly Travers |
MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions. |
Pharmaceutical Executive
March 1, 2007 |
Finance: Q&A with Annette Grimaldi It's now more lucrative for a small pharmaceutical company to sell than to go public. Here is how the past year has shaped up - and what might be next on the horizon. |
Bio-IT World
May 2006
Mark D. Uehling |
Bio-IT World CTMS Survey An online survey of the clinical trial management system market reveals some divergences between how the pharma/biotech folks and the contract research folks see the CTMS landscape. Are our respondents happy with the CTMS landscape? |
The Motley Fool
January 28, 2008
Brian Lawler |
A Great Way to Recession-Proof Your Portfolio If you want a recession resistant portfolio, invest in large cap pharmaceuticals. |
Pharmaceutical Executive
July 10, 2014
William Looney |
Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
Knowledge@Wharton
March 26, 2003 |
Health Care Finance Industry Plagued by Lack of Funding, Focus In today's health care finance environment, early financing rounds are harder to fund and the market for initial public financings is dead, with no revival expected anytime soon. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
Pharmaceutical Executive
June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
The Motley Fool
February 25, 2004
Brian Gorman |
Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry. |
The Motley Fool
April 29, 2011
Brian Orelli |
Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves. |
Bio-IT World
August 2005
G. Steven Burrill |
Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market. |
BusinessWeek
July 12, 2004
Kerry Capell |
These Biotechs Need Time To Ripen A rush to the IPO market in Europe won't do the biotech industry any good. |
The Motley Fool
December 21, 2004
Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
Financial Planning
April 1, 2006
Donald Jay Korn |
Rx for Investing Healthcare stocks may cure investors' ills over the long term, but the current prognosis is less clear. For clients in diversified funds, planners should decide whether additional healthcare exposure is justified, through individual stocks or specialized funds. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
The Motley Fool
July 24, 2007
Brian Lawler |
Schering Doesn't Slow Schering-Plough continues its strong sales and earnings growth, but it has a big acquisition to digest in coming quarters. |
Chemistry World
January 11, 2013
Andrew Turley |
Pharma industry 'strategic crisis' The pharma industry is grappling with a 'strategic crisis' according to three quarters of companies surveyed in a report from consultancy firm Roland Berger. |
The Motley Fool
September 30, 2008
Brian Orelli |
Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside. |
The Motley Fool
July 12, 2004
Ben McClure |
Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good. |
The Motley Fool
February 17, 2011
Brian Orelli |
What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate. |
BusinessWeek
March 26, 2007
Arlene Weintraub |
Biotech's Unlikely New Pal Can private equity manage its big risks and far-off returns? |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
Pharmaceutical Executive
January 1, 2009
Stan Bernard |
Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms. |
Fast Company
February 2009
Elizabeth Svoboda |
Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits. |
